GovChime
Notice ID: 4d39d4910f9342ab884a17da65073c2aSpecial Notice

NMRC Bone Marrow Program

Archived on June 6, 2024. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
12:00 PM UTC−04:00
Posted
May 7, 2024
Notice type
Special Notice
Agency
Department of WarDepartment of the Navy

Notice details

Office
NAVAL MEDICAL RESEARCH CENTER
Place of performance
Silver Spring, MD, 20910
Last updated
Dec 4, 2025

Identifiers

Solicitation number
N3239824Q9982
Notice ID
4d39d4910f9342ab884a17da65073c2a

Description

The United States Department Of Naval Medical Research Command (NMRC) intends to award a sole source contract, CareDX Lab Solutions., West Chester, PA. 19382. This notice is not a request for competitive proposals however If interested Government shall consider all responses. The DoD Bone Marrow Program mission in the treatment of radiation and chemical weapon exposure is unique to the Armed Forces. When prescribed 90% of drugs work only in 30-50% this is because 90% of individuals are likely to have different clinically actionable pharmacogenetic genotype. There is a strong and well documented correlation between drug efficacy and variation in genes responsible for drug metabolism or transport (Pharmacogenetics; PGx). Maintaining an optimal level of immunosuppression is critical for successful post-transplant management after HSCT. Too low level of immunosuppression might lead to GvHD and relapse, whereas too high level of immunosuppression might lead to toxicity and deleterious side effects. Metabolism and efficacy of most commonly used immunosuppressive drugs are modulated by pharmacogenes. Variations in pharmacogenes are widespread across different populations, with many of them frequent in minority groups. Genetic testing allows for identification of patients carrying deleterious variants in pharmacogenes. The proposed action is the continuation of research to develop an NGS-based assay using hybrid capture technology to assess response to various immunosuppression protocols (drugs) in the surveillance of HSCT patients. 1. Stage 1 Optimization Personnel Hours 2. Stage 1 Optimization Reagents Cost 3. Stage 2 Verification Personnel Hours 4. Stage 2 Verification Reagents Cost 5. Stage 3 Software Development - Initiation phase Personnel hours Period Of Performance Sep 2024 - May 2025. The NAICS code for this action is 621511. This requirement will be procured under the guidelines of FAR Part 12 Commercial Items. NMRC requires that all contractors doing business with the Acquisition Office must be registered with the Systems for Award Management (SAM). No award can be made unless the vendor is registered in Systems for Award Management. For additional information and to register in SAM, please access the following website: https://www.sam.gov/. In order to register with the SAM and to be eligible to receive an award from this Acquisition Office, all offers must have a Unique Entity Identification Number (UEI). A Sam.gov number may be acquired free of charge by contacting Sam.gov online at www.sam.gov or by phone at (866) 606-8220. See attached J&A for specifics. Email your Quote to the following: shamai.m.carter.civ@health.mil deborah.m.sharpe2.civ@health.mil

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:N3239824Q9982
  1. Special NoticeCurrentMay 7, 2024

    NMRC Bone Marrow Program

    Notice 4d39d4910f9342ab884a17da65073c2a on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

N3239824Q9982

Archive Date

Jun 6, 2024

Office Address

SILVER SPRING, MD, 20910-7500